false
English
Catalog
2023 World Conference on Lung Cancer (Posters)
EP11.03. Real World Outcomes after Chemotherapy an ...
EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe - PDF(Slides)
Back to course
Pdf Summary
A retrospective study was conducted to examine the real-world treatment patterns and outcomes in European patients with metastatic non-small cell lung cancer (mNSCLC) who had progressed on platinum-doublet chemotherapy and anti-PD(L)1 therapy. The study aimed to assess overall survival (OS), real-world time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) in this population.<br /><br />The study included European patients with mNSCLC who had progressed on therapy with one anti-PD(L)1 and platinum-doublet chemotherapy regimen and had initiated a subsequent line of therapy between June 1st, 2017 and November 30th, 2021. Data from patient charts were collected through a physician panel-based medical chart review.<br /><br />The study found that the most common treatment regimens observed after progression on platinum-doublet chemotherapy and anti-PD(L)1 were non-platinum chemotherapy, non-platinum chemotherapy with VEGF(R) inhibitors, and platinum-doublet chemotherapy. The median overall survival was shorter than one year, indicating an unmet clinical need for more efficacious therapies for this patient population.<br /><br />The study had some limitations, including the collection of de-identified data through a physician panel, which may limit the generalizability of the findings to the overall practice of oncologists/pulmonologists. Additionally, the study focused on patients from Germany, France, and the United Kingdom, so the findings may not be generalizable to patients outside of these countries.<br /><br />In conclusion, this study provides real-world data on treatment patterns and outcomes in European patients with mNSCLC who had progressed on platinum-doublet chemotherapy and anti-PD(L)1 therapy. The findings highlight the need for more effective treatment options for patients in this population.
Asset Subtitle
Ticiana Leal
Meta Tag
Speaker
Ticiana Leal
Topic
Metastatic NSCLC: Immunotherapy - Retrospective
Keywords
retrospective study
real-world treatment patterns
metastatic non-small cell lung cancer
platinum-doublet chemotherapy
anti-PD(L)1 therapy
overall survival
time-to-treatment discontinuation
progression-free survival
treatment regimens
efficacious therapies
×
Please select your language
1
English
5
普通话
11
Dutch